- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 10.06. | Anteris Technologies Global Corp.: Anteris Appoints David Roberts and Gregory Moss to its Board of Directors | 1 | GlobeNewswire (USA) | ||
| 09.06. | Anteris Technologies ernennt neue Vorstandsmitglieder und gibt Rücktritt bekannt | 2 | Investing.com Deutsch | ||
| 09.06. | Anteris Technologies Global Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 13.05. | Anteris Technologies Global Corp.: Anteris Announces Results for the First Quarter of 2025 | 240 | GlobeNewswire (Europe) | MINNEAPOLIS and BRISBANE, Australia, May 13, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed... ► Artikel lesen | |
| ANTERIS TECHNOLOGIES GLOBAL Aktie jetzt für 0€ handeln | |||||
| 13.05. | Anteris Technologies Global Corp. - 10-Q, Quarterly Report | 1 | SEC Filings | ||
| 29.04. | Anteris Technologies Global Corp. - 10-K/A, Annual Report | - | SEC Filings | ||
| 31.03. | Anteris meldet über 100 Patienten, die mit neuer Herzklappe behandelt wurden | 2 | Investing.com Deutsch | ||
| 31.03. | Anteris reports over 100 patients treated with new heart valve | 1 | Investing.com | ||
| 31.03. | Anteris Technologies Global Corp.: Anteris Technologies Reaches Clinical Milestone: 100 patients treated with DurAVR THV | 260 | GlobeNewswire (Europe) | MINNEAPOLIS and BRISBANE, Australia, March 31, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris® or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed... ► Artikel lesen | |
| 31.03. | Anteris Technologies Global Corp. - 8-K, Current Report | 1 | SEC Filings | ||
| 17.03. | Elutia stock soars, Anteris falls in medical devices sector | 4 | Investing.com | ||
| 13.03. | Anteris Technologies Global Corp. reports FY results | 1 | Seeking Alpha | ||
| 13.03. | Anteris Technologies Global Corp.: Anteris Reports 2024 Financial Results and Provides Corporate Update | 305 | GlobeNewswire (Europe) | EAGAN, Minn. and BRISBANE, Australia, March 12, 2025 (GLOBE NEWSWIRE) -- Anteris Technologies Global Corp. (Anteris or the Company) (NASDAQ: AVR, ASX: AVR) a global structural heart company committed... ► Artikel lesen | |
| 12.03. | Anteris Technologies Global Corp. - 10-K, Annual Report | 2 | SEC Filings | ||
| 06.03. | Anteris Technologies Global Corp. - 8-K, Current Report | - | SEC Filings | ||
| 15.01. | Anteris Technologies Global Corp. - 8-K, Current Report | - | SEC Filings | ||
| 13.12.24 | Anteris Technologies Prices 14.80 Mln Shares IPO At $6/shr | 756 | AFX News | CANBERA (dpa-AFX) - Anteris Technologies Global Corp. or ATGC, an Australian structural heart company, announced Friday that it has priced its initial public offering of 14.80 million shares... ► Artikel lesen | |
| 13.12.24 | Anteris Technologies Global Corp. Announces Pricing of U.S. Initial Public Offering | 228 | Business Wire | BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Global Corp. ("ATGC") today announced the pricing of its initial public offering of 14,800,000 shares of its common stock... ► Artikel lesen | |
| 09.12.24 | Anteris Technologies Global Corp. Announces Launch of U.S. Initial Public Offering | 224 | Business Wire | BRISBANE, Australia & EAGAN, Minn.--(BUSINESS WIRE)--Anteris Technologies Global Corp. ("ATGC") today announced that it has launched the roadshow for its proposed initial public offering of 14... ► Artikel lesen | |
| 25.11.24 | Anteris Technologies Global Corp. Files Registration Statement For U.S. IPO | 586 | AFX News | WASHINGTON (dpa-AFX) - Anteris Technologies Global Corp. announced that it has filed a Registration Statement on Form S-1 with the U.S. Securities and Exchange Commission, relating to the proposed... ► Artikel lesen |
1 2 Weiter >>
21 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| SERNOVA BIOTHERAPEUTICS | 0,100 | +8,70 % | Sernova Biotherapeutics, Inc.: Sernova Appoints Jonathan Rigby as Interim Chair | LONDON, Ontario and BOSTON, June 02, 2025 (GLOBE NEWSWIRE) -- Sernova Biotherapeutics, (TSX: SVA) (OTCQB: SEOVF) (FSE/XETRA: PSH), a leading regenerative medicine company focused on developing its... ► Artikel lesen | |
| FAMICORD | 4,320 | 0,00 % | Original-Research: FamiCord AG (von Montega AG): Kaufen | Original-Research: FamiCord AG - von Montega AG 06.06.2025 / 17:08 CET/CEST Veröffentlichung einer Research, übermittelt durch EQS News - ein Service der EQS Group. Für den Inhalt der Mitteilung... ► Artikel lesen | |
| GERATHERM MEDICAL | 3,090 | -1,59 % | Geratherm Medical AG: GJ24 war herausfordernd, vorsichtige Prognose für GJ25; mwb research bekräftigt KAUFEN | Die Ergebnisse von Geratherm für das Geschäftsjahr 2024 zeigten einen Umsatzrückgang von 33% auf 14,0?Mio.?EUR, was in erster Linie auf deutliche Rückgänge in den Bereichen Healthcare Diagnostics und... ► Artikel lesen | |
| PLUS THERAPEUTICS | 0,308 | 0,00 % | Plus Therapeutics Inc.: Plus Therapeutics Announces FDA Agreement to Initiate ReSPECT-LM Dose Optimization Trial for REYOBIQ in Leptomeningeal Metastases | Primary objective to determine optimal dosing schedule for a registrational trial Trial builds on recommended Phase 2 dose determined in completed Phase 1 trial Trial benefits from $17.6M award... ► Artikel lesen | |
| ATOSSA THERAPEUTICS | 0,702 | -0,99 % | Atossa Genetics Year-end 2024 slides: (Z)-endoxifen shows promise, expenses decline | ||
| MEDICLIN | 2,880 | 0,00 % | EQS-News: MEDICLIN AG: Ordentliche Hauptversammlung stimmt allen Beschlussvorschlägen zu | EQS-News: MEDICLIN AG
/ Schlagwort(e): Hauptversammlung
MEDICLIN AG: Ordentliche Hauptversammlung stimmt allen Beschlussvorschlägen zu
04.06.2025 / 13:27 CET/CEST
Für... ► Artikel lesen | |
| PING AN HEALTHCARE | 0,976 | +0,02 % | PA GOODDOCTOR (01833): POLL RESULTS OF THE ANNUAL GENERAL MEETING HELD ON 26 JUNE 2025 | ||
| EVOFEM BIOSCIENCES | - | - | Windtree Therapeutics: Windtree Advances Lower Cost Manufacturing of PHEXXI, Evofem's Hormone-Free, On-Demand Prescription Contraceptive Gel | Windtree rapidly advancing lower cost PHEXXI manufacturing under March 2025 sourcing agreement Contract inked with outside U.S manufacturer to cut PHEXXI manufacturing costs by over 50% by end of... ► Artikel lesen | |
| PROCEPT BIOROBOTICS | 58,18 | 0,00 % | PROCEPT BioRobotics Reports Fourth Quarter and Full Year 2024 Results | SAN JOSE, Calif., Feb. 25, 2025 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the "Company"), a surgical robotics company focused on advancing patient care by developing transformative... ► Artikel lesen | |
| CAPSOVISION | 3,500 | 0,00 % | CapsoVision Prices IPO Of 5.50 Mln Shares At $5.00/shr | WASHINGTON (dpa-AFX) - CapsoVision Inc. (CV), a commercial-stage medical technology company that develops
advanced imaging and artificial intelligence technologies that are deployed in its... ► Artikel lesen | |
| BRIGHTSPRING HEALTH SERVICES | 22,010 | 0,00 % | BrightSpring Health Leads Companies In Line For Triple-Digit Profit Growth | ||
| ALIGNMENT HEALTHCARE | 13,610 | -4,22 % | Alignment Healthcare Reports Strong First Quarter 2025 Results; Exceeds High-End of Expectations On 4 Critical KPIs; Raises Midpoint of 2025 Guidance; Announces CFO Transition | Delivers Q1 revenue of $926.9 million, up 47.5% year over year, and grows Medicare Advantage (MA) membership by 31.7% to approximately 217,500 membersExceeds high-end of Q1 guidance on membership... ► Artikel lesen | |
| FRESENIUS MEDICAL CARE | 47,710 | -1,26 % | UBS stuft FMC FRESENIUS MEDICAL CARE AG auf 'Neutral' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat FMC auf "Neutral" belassen. In Gesprächen mit Investoren in Europa habe er ein gestiegenes Interesse an Medizintechnikunternehmen festgestellt... ► Artikel lesen | |
| MIMEDX | 6,230 | 0,00 % | MiMedx Group, Inc: MIMEDX Announces First Quarter 2025 Operating and Financial Results | Net Sales of $88 million Grew 4% Year-Over-Year for the First Quarter First Quarter GAAP Net Income and Earnings Per Share were $7 Million and $0.05, Respectively First Quarter Adjusted EBITDA... ► Artikel lesen | |
| FRESENIUS | 42,300 | +0,05 % | UBS stuft Fresenius SE auf 'Buy' | ZÜRICH (dpa-AFX Analyser) - Die Schweizer Großbank UBS hat Fresenius auf "Buy" belassen. In Gesprächen mit Investoren in Europa habe er ein gestiegenes Interesse an Medizintechnikunternehmen festgestellt... ► Artikel lesen |
Das Unternehmen ANTERIS TECHNOLOGIES GLOBAL CORP kann der Branche Gesundheitswesen zugeordnet werden. Die relative Kursveränderung beträgt aktuell -0,54 % bei einem Aktienkurs von 3,700 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und .
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ANTERIS TECHNOLOGIES GLOBAL CORP finden Sie auf Wallstreet Online.